Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
Amgen (AMGN): Obesity Pipeline Emerges as Growth Engine , Is MariTide the Pivotal Catalyst for the Next Cycle: What’s the Pipeline Impact, Valuation Outlook & its 5 Key Catalysts ?
Amgen’s Q2 2025 results highlighted strong operational execution with revenue up 9% YoY to $9.2B and EPS growth of 21%, underpinned by 13% volume expansion that offset structural pricing pressure. Performance was broad-based with 15 products delivering double-digit gains, led by Repatha (+31%), EVENITY (+32%), UPLIZNA (+91%), and TEZSPIRE (+46%), while oncology momentum was reinforced by BLINCYTO (+45%) and the early IMDELLTRA launch ($134M). Rare disease and general medicine franchises continue to expand, validating portfolio durability. Pipeline visibility remains a central theme, with MariTide anchoring Amgen’s obesity strategy; Phase III programs point to differentiated efficacy, monthly dosing, and improved GI tolerability, which could transform Amgen’s metabolic footprint if execution aligns with expectations. Complementary assets such as olpasiran (OCEAN(a)), Repatha (VESALIUS), and bemarituzumab add depth to the late-stage pipeline, though binary outcomes remain a key risk. Management reaffirmed FY25 revenue guidance of $35–36B and EPS of $20.20–$21.30, while increasing R&D spend >20% YoY to accelerate late-stage programs. Biosimilars added $661M (+40% YoY) and remain an underappreciated contributor, though Prolia erosion underscores competitive headwinds. With MariTide’s clinical trajectory set to define Amgen’s next growth cycle, will its differentiated obesity profile catalyze a structural re-rating and drive durable long-cycle value creation across the broader pipeline?
